Raymond James & Associates Cognition Therapeutics Inc Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding CGTX
# of Institutions
57Shares Held
13.1MCall Options Held
0Put Options Held
0-
Bios Capital Management, LP Fort Worth, TX6MShares$6.6 Million2.56% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ2.21MShares$2.43 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.3MShares$1.43 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA702KShares$772,1340.0% of portfolio
-
Voss Capital, LLC Houston, TX450KShares$495,0000.02% of portfolio
About COGNITION THERAPEUTICS INC
- Ticker CGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,710,700
- Market Cap $25M
- Description
- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...